论文部分内容阅读
近年来人们应用Fab′和IgG两种抗CD-22的免疫毒素(ITs),对治疗难治性非何杰金氏淋巴瘤病人进行临床试验,但由于这些病人通常伴有巨大肿瘤,而ITs最适宜于残留微小肿瘤的治疗,所以在Ⅰ期临床试验中比较最佳有效剂量和用药途径是困难的。本文作者将B淋巴细胞瘤细胞(Dandi细胞)接种到患有联合免疫缺陷病(SCID)的鼠体中,制造出一个鼠模型(SCID-Dandi小鼠),用此模型比较ITs的抗肿瘤作用。结果表明:两种ITs中,Fab′-dgA
In recent years, people have applied Fab’ and IgG two anti-CD-22 immunotoxins (ITs) for clinical trials of refractory non-Hodgkin’s lymphoma patients, but these patients are usually associated with large tumors, and ITs It is most suitable for the treatment of residual microscopic tumors, so it is difficult to compare the best effective dose and route of administration in Phase I clinical trials. The authors inoculated B-lymphoma cells (Dandi cells) into mice with combined immunodeficiency disease (SCID) to create a murine model (SCID-Dandi mice) and used this model to compare the anti-tumor effects of ITs. . The results showed that Fab′-dgA was the two types of ITs.